Brookline Capital Markets Assumes Oncternal Therapeutics (ONCT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ONCT Hot Sheet
Price: $0.53 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Brookline Capital Markets analyst Kemp Dolliver assumes coverage on Oncternal Therapeutics (NASDAQ: ONCT) with a Buy rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Oncternal Therapeutics click here. For more ratings news on Oncternal Therapeutics click here.
Shares of Oncternal Therapeutics closed at $1.03 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts Anthropic (ANT), Defers Offering Rating
- Northland Starts Digital Turbine (APPS) at Outperform, 'Proven Turnaround'
- William Blair Starts ExxonMobil (XOM) at Market Perform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
